Zobrazeno 1 - 10
of 134
pro vyhledávání: '"Veristrat"'
Autor:
Bo Jia, Zhi Dong, Di Wu, Jun Zhao, Meina Wu, Tongtong An, Yuyan Wang, Minglei Zhuo, Jianjie Li, Yang Wang, Jie Zhang, Xinghui Zhao, Sheng Li, Junfeng Li, Menglei Ma, Chen Chen, Xue Yang, Jia Zhong, Hanxiao Chen, Jingjing Wang, Yujia Chi, Xiaoyu Zhai, Song Cui, Rong Zhang, Qingwei Ma, Jian Fang, Ziping Wang
Publikováno v:
Cancer Cell International, Vol 20, Iss 1, Pp 1-7 (2020)
Abstract Background Although advanced non-squamous non-small cell lung cancer (NSCLC) patients have significantly better survival outcomes after pemetrexed based treatment, a subset of patients still show intrinsic resistance and progress rapidly. Th
Externí odkaz:
https://doaj.org/article/442dc4d633c04047b3e301b119b02ba9
Autor:
Mary Jo Fidler, Cristina L. Fhied, Joanna Roder, Sanjib Basu, Selina Sayidine, Ibtihaj Fughhi, Mark Pool, Marta Batus, Philip Bonomi, Jeffrey A. Borgia
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-9 (2018)
Abstract Background The VeriStrat test is a serum proteomic signature originally discovered in non-responders to second line gefitinib treatment and subsequently used to predict differential benefit from erlotinib versus chemotherapy in previously tr
Externí odkaz:
https://doaj.org/article/50ebd1b8392c48aa9f668f55a3ffc1c6
Autor:
Olga Efimova, Brygida Berse, Daniel W. Denhalter, Scott L. DuVall, Kelly K. Filipski, Michael Icardi, Michael J. Kelley, Julie A. Lynch
Publikováno v:
BMC Medical Informatics and Decision Making, Vol 17, Iss 1, Pp 1-8 (2017)
Abstract Background Current clinical guidelines recommend epidermal growth factor receptor (EGFR) mutational testing in patients with metastatic non-small cell lung cancer (NSCLC) to predict the benefit of the tyrosine kinase inhibitor erlotinib as f
Externí odkaz:
https://doaj.org/article/3d478c1b7eaf418391bcb859a5898ca9
Autor:
Chen Chen, Minglei Zhuo, Di Wu, Yujia Chi, Sheng Li, Yuyan Wang, Xue Yang, Jingjing Wang, Zhi Dong, Rong Zhang, Meina Wu, Jia Zhong, Junfeng Li, Xiaoyu Zhai, Qingwei Ma, Hanxiao Chen, Jian Fang, Song Cui, Jie Zhang, Menglei Ma, Yang Wang, Tongtong An, Jianjie Li, Xinghui Zhao, Ziping Wang, Jun Zhao, Bo Jia
Publikováno v:
Cancer Cell International, Vol 20, Iss 1, Pp 1-7 (2020)
Cancer Cell International
Cancer Cell International
Background Although advanced non-squamous non-small cell lung cancer (NSCLC) patients have significantly better survival outcomes after pemetrexed based treatment, a subset of patients still show intrinsic resistance and progress rapidly. Therefore w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1aaa02a0414ed851e36f668d886cbcc1
https://doaj.org/article/442dc4d633c04047b3e301b119b02ba9
https://doaj.org/article/442dc4d633c04047b3e301b119b02ba9
Autor:
Robin M. Rudd, Richard Jones, Alex Edwards, Siow Ming Lee, Matthew Hatton, Allan Hackshaw, Geraldine Skailes, Elizabeth Toy, Yenting Ngai, Sunil Upadhyay, Penella J. Woll, Stephen Falk, Rohit Lal, Conrad R. Lewanski
Publikováno v:
European Journal of Cancer
Purpose We previously demonstrated that the median survival of patients with poor prognosis non–small cell lung cancer (NSCLC) considered unfit for first-line platinum chemotherapy was
Highlights • 83% advanced NSCLC patients unfit for chemo
Highlights • 83% advanced NSCLC patients unfit for chemo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a7843ac98a551237a56e4062a17ef85
https://doi.org/10.1016/j.ejca.2019.07.025
https://doi.org/10.1016/j.ejca.2019.07.025
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Joanna Roder, Maria Giovanna Dal Bello, Giulia Barletta, Krista Meyer, Heinrich Roder, Federica Biello, Francesco Grossi, Carlo Genova, Erika Rijavec, Julia Grigorieva
Publikováno v:
Lung Cancer. 117:64-69
Objectives VeriStrat® is a blood-based test that utilizes matrix-assisted laser desorption/ionization time-of-flight (MALDI ToF) mass spectrometry to assign a binary classification of VeriStrat Good or VeriStrat Poor that is associated with treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdc70637535040768f6e509daa34fac5
https://doi.org/10.1016/j.lungcan.2017.12.007
https://doi.org/10.1016/j.lungcan.2017.12.007
Autor:
Jeffrey A. Borgia, Mary J. Fidler, Selina Sayidine, Marta Batus, Sanjib Basu, Ibtihaj Fughhi, Joanna Roder, Cristina Fhied, Philip Bonomi, Mark Pool
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-9 (2018)
BMC Cancer
BMC Cancer
Background The VeriStrat test is a serum proteomic signature originally discovered in non-responders to second line gefitinib treatment and subsequently used to predict differential benefit from erlotinib versus chemotherapy in previously treated adv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aacf4e4c35509f6196eb3f818f2286f2
http://link.springer.com/article/10.1186/s12885-018-4193-0
http://link.springer.com/article/10.1186/s12885-018-4193-0
Autor:
Brygida Berse, Kelly K. Filipski, Michael S. Icardi, Scott L. DuVall, Olga Efimova, Daniel W. Denhalter, Michael J. Kelley, Julie Lynch
Publikováno v:
BMC Medical Informatics and Decision Making, Vol 17, Iss 1, Pp 1-8 (2017)
BMC Medical Informatics and Decision Making
BMC Medical Informatics and Decision Making
Background Current clinical guidelines recommend epidermal growth factor receptor (EGFR) mutational testing in patients with metastatic non-small cell lung cancer (NSCLC) to predict the benefit of the tyrosine kinase inhibitor erlotinib as first-line
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e485c432aac4cad56f003bc1cb46019
http://link.springer.com/article/10.1186/s12911-017-0475-8
http://link.springer.com/article/10.1186/s12911-017-0475-8